Mentshlichkeit* (8.7.2026)
Dr. Jack Cush reviews the news and recent journal reports on RheumNow.com.
Read Article
Rethinking Treatment of EGPA
Like MPA & GPA, the goals of EGPA are controlling initial organ damage and preventing relapse. But EGPA has the added challenge of chronic upper and lower respiratory tract involvement, allergic type 2 inflammations and risk of glucocorticoid https://t.co/KIVpyhsghg
Dr. John Cush @RheumNow( View Tweet )
New Avacopan Analysis Sent to FDA
After data manipulation allegations, the FDA has been calling for the vasculitis drug to be pulled from the market since January.
Amgen has submitted a third-party review of avacopan's (Tavneos) pivotal trial data and other analyses to the FDA https://t.co/zBg4pFBfSP
Dr. John Cush @RheumNow( View Tweet )
Rethinking Treatment of EGPA
Eosinophilic granulomatosis with polyangiitis (EGPA) has long been managed by extrapolating results from microscopic polyangiitis and granulomatosis with polyangiitis clinical trials. But new insights into EGPA's has lead to advances in therapy and new treatment paradigms.
Read Article
New Avacopan Analysis Sent to FDA
After data manipulation allegations, the FDA has been calling for the vasculitis drug to be pulled from the market since January.
Amgen has submitted a third-party review of avacopan's (Tavneos) pivotal trial data and other analyses to the FDA https://t.co/TdLWRMPvnR
Dr. John Cush @RheumNow( View Tweet )
New Avacopan Analysis Sent to FDA
MedPage Today
After data manipulation allegations, the FDA has been calling for the vasculitis drug to be pulled from the market since January.
Amgen has submitted a third-party review of avacopan's (Tavneos) pivotal trial data and other analyses to the FDA in a bid to keep the embattled drug for
Read Article
Gout Cavalcade (7.10.2026)
Dr. Jack Cush reviews the news, journal articles and regulatory decisions from the past week. July is Gout: More than Flares month.
Read Article
NEJM Retracts Pivotal ADVOCATE Trial of FDA-Approved Avacopan
The New England Journal of Medicine (NEJM) retracted the pivotal study supporting FDA's approval of avacopan (Tavneos) for severe forms of anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis. https://t.co/GOVyk5poNq
Dr. John Cush @RheumNow( View Tweet )
NEJM Retracts Pivotal ADVOCATE Trial of FDA-Approved Avacopan
MedPage Today
The New England Journal of Medicine (NEJM) retracted the pivotal study supporting FDA's approval of avacopan (Tavneos) for severe forms of anti-neutrophil
Read Article
DERM on RheumNow (June 2026)
The Derm on RheumNow podcast is a collection of Citations and Content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, other CTD skin disorders. dermatology drugs, biologics, JAKs - their use, efficacy and side effects. https://t.co/vy4BAx8Lnq
Dr. John Cush @RheumNow( View Tweet )
EULAR26: Vasculitis updates: Glucorticoid use in AAV and GCA
EurekAlert!
EULAR recommends a combination of glucocorticoids with either rituximab or cyclophosphamide for remission induction in life-threatening or organ-threatening AAV, followed by gradual tapering of glucocorticoids.
Read Article
ICYMI: EGPA Review
A current review of eosinophilic granulomatosis with polyangiitis (EGPA) provides current recommendations on diagnosis and management.
Read Article
2-Gene Blood Test for Kawasaki Disease in Febrile Children
JAMA Network Open has publshed that a simple 2-gene blood test may aid the earlier diagnosis of Kawasaki disease in children with febrile illnesses.
Read Article
EULAR 2026 Recommendations on PMR, GCA, and Takayasu Arteritis
On the final day of EULAR, Mukhtyar et al (on behalf of a large international task force) presented the updated EULAR recommendations for management of PMR, GCA, and TAK. There were 5 overarching principles and 12 https://t.co/kpykylEbsr
Dr. John Cush @RheumNow( View Tweet )
Do You Zoster Vaccinate? (6.19.2026)
Dr. Jack Cush reviews the news, journal reports and best ways to review EULAR 2026.
Read Article
EULAR 2026 Recommendations on PMR, GCA, and Takayasu Arteritis
On the final day of EULAR 2026, Mukhtyar et al (on behalf of a large international task force) presented the updated EULAR recommendations for management of polymyalgia rheumatica (PMR), giant cell arteritis (GCA), and Takayasu arteritis (TAK). There were 5 overarching principles and 12
Read Article
Vasculitis Updates: Glucocorticoid use in AAV and GCA
Vasculitis Updates: Glucocorticoids are the cornerstone of initial therapy for AAV and GCA—quickly reducing inflammation and preserving organs. EULAR has issued recommendations on glucocorticoid use in ANCA‑associated and https://t.co/hIOKyXDxyb
Dr. John Cush @RheumNow( View Tweet )
EULAR 2026 Rheumatology RoundUp
It’s time for Rheumatology RoundUp from EULAR 2026 from London, UK. Drs. Artie Kavanaugh and Jack Cush review their choice presentations from the meeting, offering their perspectives on impact and applicability.
Read Article
Day 4 EULAR Report
The last day in London was exciting as both the Late-Breaking abstracts and new EULAR guidelines were presented. Guidelines presented addressed several significant unmet need areas including PMR, GCA, Takayasu’s arteritis, Vaccinations in Rheumatic patients, Imaging in spondyloarthritis and
Read Article
Prospective study of RVZ immunogenicity = heterogeneous cellular immunity across RMDs
12mo 150 pts
-CD4+ gE-T-cell response peaks mo 3
-Response seen in axSpA + GCA, but not RA
-25% of patients no CMI increase after vaccination
Consistent w/other vaccine cellular imm profiles https://t.co/yvDLSHh4Bj
Aurelie Najm @AurelieRheumo( View Tweet )
Day 2 Report from EULAR 2026
Day two at EULAR 2026 was jammed with sessions on advances in immune checkpoint inhhbitors (and irAEs), Lupus, Scleroderma, RA and IgG4 related disease. Here are a few of my favorites from Day 2.
Read Article
Vasculitis Updates: Glucocorticoid use in AAV and GCA
2026 EULAR Press Release
Glucocorticoids are the cornerstone of initial vasculitis treatment, used to rapidly control inflammation and protect vital organs. EULAR has recommendations that cover glucocorticoid use in ANCA associated vasculitides (AAV) and large vessel vasculitis, including giant cell arteritis (GCA).1,2
Read Article
#EULAR2026 OP028 In 16 patients with AID (SSc,IIM, RA, IgG4,SjD, Grave’s), CD3xBCMA BiTE, Teclistamab was effective in 15/16. Duration of GC & DMARD-free was 11 mths. 2/16 need retreatment. All had low IgG and needed IVIG. Need long-term safety data & comparative study @RheumNow https://t.co/97MUPnXRua
Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
DERM on RheumNow PODCAST (May 2026)
The Derm on RheumNow podcast is a collection of Citations and Content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, and other CTD skin disorders. Dermatology drugs, biologics, JAKs - their use, efficacy, and https://t.co/0AEAxadBFT
Dr. John Cush @RheumNow( View Tweet )
Quiz Talk (5.22.2026)
Dr. Jack Cush talks of birthdays, Quizzes and journal articles this week on the podcast.
Read ArticleTherapeutic Updates
A review of two physician case reports. These cases are patients who presented with severe active manifestations of granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA).
Read Post
Diagnosis of PMR
RheumNow
Nine perspectives now available: Red Flags in the Diagnosis of PMR; Epidemiology of PMR; Role of the PCP in Diagnosis and Care; Importance of Diagnostic Imaging; ESR/CRP in PMR; PMR Must Rule Outs; Which PMR Patients Should Rheumatologists See?; Is There Hidden GCA?; and PMR Mimics.
Read Post
Recent Blogs
At first, it seemed similar to many other such sessions – a circle of folding chairs, a group of colleagues whose visages exuded understanding and acceptance – but this was special. I started the meeting…. “Hi, my name is Artie.”
Read Post
At first, it seemed similar to many other such sessions – a circle of folding chairs, a group of colleagues whose visages exuded understanding and acceptance – but this was special. I started the meeting…. “Hi, my name is Artie.”
Read Post
Please don’t tell your patient that PMR “typically” lasts two years. According to real-world data from the UK, one in four patients with PMR is prescribed steroids by their primary care physician for over four years. But nobody tells them this at the start, and that causes big problems later on.
Read Post
Podcasts
ACR 2025 Daily Podcasts Day3b-
ACR 2025 Daily Podcasts Day2a
-
ACR 2025 Daily Podcasts Day1c
